Company intelligence / Profile preview

HeartBug

Ownership: Private
Development stage: Commercial

Overview

HeartBug provides a commercially available, non-invasive personal ECG monitor for up to 28 days of continuous cardiac rhythm tracking. It is widely used by cardiologists in Australia for diagnosing intermittent arrhythmias and atrial fibrillation. The device offers higher diagnostic yield than traditional Holter monitors due to its extended wear time and real-time data transmission capabilities. Clinical results are interpreted by specialist electrophysiologist cardiologists.[1][3]

Therapeutic areas: Cardiovascular
Modalities: DeviceNon-pharmacological therapyDigital health solution (remote cardiac monitoring)
Industry: Physiological Monitoring

Partnerships

Collaboration with Australian cardiology clinics/hospitals nationwide (~750 out of ~1000 cardiologists in Australia use the service)[1]

Beyond the preview

Go deeper on HeartBug.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HeartBug.

Explore the full profile